Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Colorectal Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Fluorouracil 98Oxaliplatin 94Leucovorin 86Irinotecan 70Gemcitabine 66Bevacizumab 62Capecitabine 60Cetuximab 42pembrolizumab 37Cisplatin 30Nivolumab 25Drug Therapy 25130-nm albumin-bound paclitaxel 22Specimen Handling 20Folfox protocol 20Panitumumab 19Paclitaxel 19Magnetic Resonance Spectroscopy 18Albumin-Bound Paclitaxel 17Biopsy 16IFL protocol 15Floxuridine 15Docetaxel 15Cyclophosphamide 15Sorafenib 14regorafenib 12Erlotinib Hydrochloride 12aflibercept 11Radiofrequency Ablation 11fludarabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × berzosertib × Gastrointestinal × Clear all
NCT02595931 2026-05-13

M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Active not recruiting
66 enrolled
GastrointestinalThoracic

Lung Neoplasms, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡